Genetic factors in the pathogenesis of primary biliary cirrhosis

Clinics in Liver Disease

Volumn 7, Issue 4, 2003, Pages 841-864

  Jones, David E J ^a   Donaldson, Peter T ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; MANNOSE BINDING LECTIN; MANNOSE BINDING PROTEIN; UNCLASSIFIED DRUG;

ALLELISM; CELLULAR IMMUNITY; CHROMOSOME 6P; DISEASE COURSE; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HEREDITY; HUMAN; IMMUNOGENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LIVER BIOPSY; PRIMARY BILIARY CIRRHOSIS; REVIEW;

EID: 0141817494     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(03)00095-3     Document Type: Review

References (140)

1. James OFW, Bhopal R, Howel D, et al. Primary biliary cirrhosis once rare, now common in the UK? Hepatology 1999;30:390-4.
2. Jones DEJ. Fetal microchimerism: an aetiological factor in primary biliary cirrhosis? J Hepatol 2000;33:834-7.
3. Prince MI, Chetwynd A, Diggle P, et al. The geographical distribution of primary biliary cirrhosis in a well-defined cohort. Hepatology 2001;34:1083-8.
4. Triger DR. Primary biliary cirrhosis: an epidemiological study. BMJ 1980;281:772-5.
5. Bach N, Schaffner F. Familial primary biliary cirrhosis. J Hepatol 1994;20:698-701.
6. Brind AM, Bray GP, Portmann BC, et al. Prevalence and pattern of familial disease in primary biliary cirrhosis. Gut 1995;36:615-7.
7. Jones DE, Watt FE, Metcalf JV, et al. Familial primary biliary cirrhosis reassessed: a geographically-based population study. J Hepatol 1999;30:402-7.
8. Wordsworth P. Genes and arthritis. Br Med Bull 1995;51:249-66.
9. Satsangi J, Welsh KI, Bunce M, et al. Contribution of genes of the major histocompatability complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996;347:1212-7.
10. Vyse TJ, Todd JA. Genetic analysis of autoimmune disease. Cell 1996;85:311-8.
11. Risch N. Assessing the role of HLA-linked and unlinked determinants of disease. Am J Hum Genet 1987;40:1-4.
12. Watt FE, Bassendine MF, James OFW, et al. A population based study of autoimmunity in primary biliary cirrhosis (PBC) patients and their families: evidence for a shared susceptibility. J Hepatol 2001;34:211.
13. Golding PL, Smith M, Williams R. Multisystem involvement in chronic liver disease. Am J Med 1973;55:772-82.
14. Clarke AK, Galbraith GM, Hamilton EBD, et al. Rheumatic disorders in primary biliary cirrhosis. Ann Rheum Dis 1978;37:42-7.
15. Culp KS, Fleming CR, Duffy J, et al. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc 1982;57:365-70.
16. Todd JA. Genetic analysis of type 1 diabetes using whole genome approaches. Proc Natl Acad Sci USA 1995;92:8560-5.
17. Selmi C, Mayo MJ, Bach N, et al. Occurrence of primary biliary cirrhosis in monozygotic twins. Hepatology 2002;36:387A.
18. Emery J, Hayflick S. The challenge of integrating genetic medicine into primary care. Br Med Bull 2001;322:1027-30.
19. Morton NE. Sequential tests for the detection of linkage. Am J Hum Genet 1955;7:277-319.
20. Davies JE, Kawaguchi Y, Bennett ST, et al. A genome wide search for human type 1 diabetes susceptibility genes. Nature 1994;371:130-6.
21. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-4.
22. Keavney B, McKenzie C, Parish S, et al. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. Lancet 2000;355:434-42.
23. Cardon LR, Bell JI. Association study designs for complex disease. Nature Reviews 2001;2:91-9.
24. Todd JA. Interpretation of results from genetic studies of multifactorial disease. Lancet 1999;354(Suppl 1):15-6.
25. Anonymous. Freely associating. Nat Genet 1999;22:1-2.
26. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000;405:847-56.
27. Milner CM, Campbell DR, Trowsdale J. Molecular genetics of the human major histocompatibility complex. In: Warrens A, Lechler R, editors. HLA in health and disease. London: Academic Press; 2000. p. 35-50.
28. Baker RJ, Warrens AN. The biology of major histocompatibility complex molecules - I. In: Warrens A, Lechler R, editors. HLA in health and disease. London: Academic Press; 2000. p. 51-72.
29. Chen AP, Purcell AW, McCluskey J. The biology of major histocompatibility complex molecules - II: antigen processing and presentation. In: Warrens A, Lechler R, editors. HLA in health and disease. London: Academic Press; 2000. p. 73-106.
30. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999;341:2068-74.
31. Matzinger P. An inate sense of danger. Semin Immunol 1998;10:399-415.
32. Nepom GT. A unified hypothesis for the complex genetics of HLA associations with IDDM. Diabetes 1990;39:1153-7.
33. Sheehy MJ. HLA and insulin-dependent diabetes: a protective perspective. Diabetes 1992;41:123-9.
34. Miyamori H, Kato Y, Kobayashi K, Hattori N. HLA antigens in Japanese patients with primary bilairy cirrhosis and autoimmune hepatitis. Digestion 1983;26:213-7.
35. Ercilla G, Pares A, Arriga F, et al. Primary biliary cirrhosis associated with DR3. Tissue Antigens 1979;14:449-52.
36. Johnston DE, Kaplan MM, Milleer KB, et al. Histocompatibility antigens in primary biliary cirrhosis. Am J Gastroenterol 1987;82:1127-9.
37. Gores GJ, Moore SB, Fisher LD, et al. Primary biliary cirrhosis: association with class II major histocompatibility complex antigens. Hepatology 1987;7:889-92.
38. Donaldson PT, Manns MP. Immunogenetics of liver disease. In: Bircher J, Benhamou J-P, McIntyre N, Rizzetto M, Rhodes J, editors. Oxford textbook of clinical hepatology. Oxford, England: Oxford University Press; 1999. p. 173-88.
39. Tanaka A, Borchers AT, Ishibashi H, et al. Genetic and familial considerations of primary biliary cirrhosis. Am J Gastroenterol 2001;96:8-15.
40. Underhill JA, Donaldson PT, Bray G, et al. Susceptibility to primary biliary cirrhosis is associated with the HLA DR8 - DQB1*0402 haplotype. Hepatology 1992;16:1404-8.
41. Donaldson P, Agarwal K, Craggs A, et al. HLA and interleukin-1 gene polymorphisms in primary biliary cirrhosis associations with disease progression and disease susceptibility. Gut 2001;48:397-402.
42. Begovich AB, Klitz W, Moonsamy PV, et al. Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis. Tissue Antigens 1994;43:71-7.
43. Stone J, Wade JA, Cauch-Dudek K, et al. Human leucocyte antigen class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Hepatol 2002;36:8-13.
44. Maeda T, Onishi S, Saibara T, et al. HLA DRw8 and primary biliary cirrhosis. Gastroenterology 1992;103:1118.
45. Seki T, Kiyosawa K, Ota M, et al. Association of primary biliary cirrhosis with human leucocyte antigen DPB1*0501 in Japanese patients. Hepatology 1993;18:73-8.
46. Oguri H, Oba S, Ogino H, et al. Susceptibility to primary biliary cirrhosis is associated with human leucocyte antigen DRB1*0803 in Japanese patients. Int Hepatolol Comm 1994;2:263-70.
47. Mukai T, Kimura A, Ishibashi H, et al. Association of HLA-DRB1*0803 and *1602 with susceptibility to primary biliary cirrhosis. Int Hepatol Comm 1995;3:207-12.
48. Manns MP, Bremm A, Schneider PM, et al. HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis. Gastroenterology 1991;101:1367-73.
49. Morling N, Dalhoff K, Fugger L, et al. DNA polymorphism of HLA class II genes primary biliary cirrhosis. Immunogenetics 1992;35:112-6.
50. Mella JG, Roschmann E, Maier K-P, et al. Association of primary biliary cirrhosis with the allele HLA-DPB1*0301 in German population. Hepatology 1995;21:398-402.
51. Underhill JA, Donaldson PT, Doherty DG, et al. HLA DPB polymorphism in primary cholangitis and primary biliary cirrhosis. Hepatology 1995;21:959-62.
52. Shimoda S, Nakamura M, Ishibashi H, et al. HLA DRB4*010-restricted immunodominant T cell autoepitope of pyruvate dehydrogease complex in primary biliary cirrhosis: Evidence of molecular mimicry in human autoimmune diseases. J Exp Med 1995;181:1835-45.
53. Donaldson PT, Czaja AJ. Genetic effects on susceptibility, expression and outcome. Clin Liver Dis 2002;6(3):419-37.
54. Norris S, Donaldson PT. Evaluation of the role of MHC class II alleles, haplotypes and amino acid sequences in primary sclerosing cholangitis. Autoimmunity 2003;35:555-64.
55. Briggs DC, Donaldson PT, Hayes P, et al. A major histocompatibility complex Class III allotype C4B2 associated with primary biliary cirrhosis. Tissue Antigens 1987;29:141-5.
56. Jones DEJ, Watt FE, Grove J, et al. Tumour necrosis factor-α promoter polymorphisms in primary biliary cirrhosis. J Hepatol 1999;30:232-6.
57. Donaldson PT. TNF polymorphisms in primary biliary cirrhosis: a critical appraisal. J Hepatol 1999;31:366-8.
58. Tanaka A, Qauranta S, Mattalia A, et al. The tumour necrosis factor-α promoter correlates with progression in primary biliary cirrhosis. J Hepatol 1999;30:826-9.
59. Gordon MA, Oppenheim E, Camp NJ, et al. Primary biliary cirrhosis shows associations with genetic polymorphism of tumour necrosis factor alpha promoter region. J Hepatol 1999;31:242-7.
60. Norris S, Kondeatis E, Collins R, et al. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: The role of MICA polymorphism. Gastroenterology 2001;120:1475-82.
61. Wiencke K, Spurkland A, Schrumpf E, et al. Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles. Hepatology 2001;34:625-30.
62. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress inducible MICA. Science 1999;285:727-9.
63. Norris S, Doherty DG, McEntee G, et al. Natural T cells in the human liver: cytotoxic lymphocytes with dual T cell and natural killer cell phenotype and function are phenotypically heterogeneous and include Vα24JαQ and γδ T cell receptor bearing cells. Hum Immunol 1999;60:20-31.
64. Martins EBG, Graham AK, Chapman RW, et al. Elevation of T lymphocytes in peripheral blood and livers of patients with primary sclerosing cholangitis and other autoimmune disease. Hepatology 1996;23:988-99.
65. Hata K, van Thiel DH, Herberman RB, et al. Phenotypic and functional characteristics of lymphocytes isolated from liver biopsy specimens from patients with active liver disease. Hepatology 1992;15:816-23.
66. McCoy KD, Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol 1999;77:1-10.
67. Kouki T, Sawai Y, Gardine CA, et al. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000;165:6606-11.
68. Perez VL, Parijs LV, Biuckians A, et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997;6:411-7.
69. Johnson GCL, Esposito L, Barratt BJ, et al. Haplotype tagging for the identification of common disease genes. Nat Genet 2001;29:233-7.
70. Kristiansen OP, Larsen ZM, Pocoit F. CTLA-4 in autoimmune diseases - a general susceptibility gene to autoimmunity? Genes Immun 2000;1:170-84.
71. Nistico L, Buzzetti CY, Pritchard LE. The CTLA4 region of chromosome 2q33 is linked to and associated with type 1 diabetes. Hum Mol Genet 1996;5:1075-89.
72. Yanagawa T, Hidaka Y, Guimaraes V. CTLA-4 gene polymorphism associated with Graves' disease in Caucasian population. J Clin Endocrinol Metabol 1995;80:41-5.
73. Maurer M, Loserth S, Kolb-Maurer A, et al. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 + 49) alters T-cell activation. Immunogenetics 2002;54:1-8.
74. Agarwal K, Czaja AJ, Jones DEJ, et al. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000;31:49-53.
75. Ligers A, Teleshova N, Masterman T, et al. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2001;2:145-52.
76. Agarwal K, Jones DEJ, Daly AK, et al. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol 2000;32:538-41.
77. Saarinen S, Broome U, Ligers A, et al. CTLA-4 gene polymorphism associated with primary sclerosing cholangitis (PSC) [abstract]. J Hepatol 1998;28:124.
78. Agarwal K, Hudson M, Harrison P, et al. No association between primary sclerosing cholangitis (PSC) and CTLA-4 gene polymorphism. Hepatology 2000;32:173A [Abstract No 44].
79. Higuchi M, Horiuchi T, Kojima T, et al. Analysis of CD40 ligand gene mutations in patients with primary biliary cirrhosis. Scand J Clin Lab Invest 1998;58:429-32.
80. Jarvelainene HA, Orpana A, Perola M, et al. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology 2001;33:1148-53.
81. Ide T, Sata M, Nakano H, et al. Increased serum IgM class anti-lipid A antibody and therapeutic effect of ursodeoxycholic acid in primary biliary cirrhosis. Hepato-Gastroenterol 1997;44:1569-73.
82. Iwata M, Harada K, Hiramatsu K, et al. Fas ligand expressing mononuclear cells around intrahepatic bile ducts co-express CD68 in primary biliary cirrhosis. Liver 2000;21:129-35.
83. Corpechot C, Poupon R. Promoter polymorphism of the CD14 endotoxin receptor gene and primary biliary cirrhosis. Hepatology 2002;35:242-3.
84. Matsushita M, Miyakawa H, Tanaka A, et al. Single nucleotide polymorphism of the mannose-binding lectin are associated with susceptibility to primary biliary cirrhosis. J Autoimmun 2001;17:251-7.
85. Blackwell JM. Structure and function of the natural-resistance-associated macrophage protein (nramp1), a candidate protein for infectious and autoimmune disease. Mol Med Today 1996;2:205-11.
86. Searle S, Blackwell JM. Evidence for a functional repeat polymorphism in the promoter of the human NRAMP1 gene that correlates with autoimmune versus infectious disease susceptibility. J Med Genet 1999;36:295-9.
87. Graham AM, Dollinger MM, Howie SM, et al. Identification of novel alleles at a polymorphic microsatellite repeat region in the human NRAMP1 gene promoter: analysis of allele frequencies in primary biliary cirrhosis. J Med Genet 2000;37:150-2.
88. Bellamy R, Ruwende C, Corrah T, et al. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med 1998;338:640-4.
89. Vilagut L, Vila J, Vinas O, et al. Cross reactivity of anti-Mycobacterium godonae antibodies with the major mitochondrial auto antigens in PBC. J Hepatol 1994;21:673-7.
90. Vilagut L, Vila J, Pares A, Vinas O, et al. Mycobacterium gordonae DNA in liver tissue of patients with primary biliary cirrhosis. J Hepatol 1998;21(Suppl):87.
91. Fanning GC, Bunce M, Black CM, et al. Polymerase chain reaction haplotyping using 3′ mismatches in the forward and reverse primers: application to the biallelic polymorphisms of tumour necrosis factor and lymphotoxin-α. Tissue Antigens 1997;50:23-31.
92. Tilg H, Diehl AM. Cytokines in alcoholic and non-alcoholic steatohepatitis. N Engl J Med 2000;343:1467-76.
93. Simpson KJ, Lukacs NW, Colletti L, et al. Cytokines and the liver. J Hepatol 1997;27:1120-32.
94. Dinarello CA. Biological basis for interleukin-1 in disease. Blood 1996;87:2095-147.
95. Laurincova B. Interleukin-1 family: from genes to human disease. Acta Univ Palacki Olomuc Fac Med 2000;143:19-29.
96. Bergholdt R, Larsen ZM, Andersen NA, et al. Characterisation of new polymorphisms in the 5′UTR of the human interleukin-1 receptor type 1 (IL1R1) gene: linkage to type 1 diabetes and correlation to IL-1R1 plasma level. Genes Immun 2000;1:495-500.
97. Bidwell J, Keen L, Gallagher G, et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 1999;1:3-19.
98. Schaekal NA, McGuiness PH, Abbott CA, et al. Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression. Gut 2001;49:565-76.
99. Eskdale J, Keijsers V, Huizinga T, et al. Microsatellites and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun 1999;1:151-5.
100. Zappala F, Grove J, Watt FE, et al. No evidence for involvement of the interleukin-10-592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis. J Hepatol 1998;28:820-3.
101. Cookson S, Constantini PK, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999;30:851-6.
102. Donaldson PT, Norris S, Constantini PK, et al. The interleukin-1 and interleukin-10 gene polymorphisms in primary sclerosing cholangitis: No associations with disease susceptibility/resistance. J Hepatol 2000;32:882-6.
103. Mitchell SA, Grove J, Spurkland A, et al. Association of the tumour necrosis factor - 308 but not the interleukin 10 - 627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut 2001;49:288-94.
104. Amano K, Takahashi H, Kuniyasu Y, et al. The combination of CTLA-4 and IFN-γ gene polymorphism is associated with susceptibility to PBC and influence on clinical manifestation. Hepatology 2001;34:371A [Abstract 797].
105. Bennett ST, Todd JA. Human type 1 diabetes and the insulin gene: principles of mapping polygenes. Annu Rev Genet 1996;30:343-70.
106. Moehario LH, Wang L, Devenish RJ, et al. The human pyruvate dehydrogenase complex: a polymorphic region of the lipoate acetyl transferase (E2) subunit gene. Biochim Biophys Acta 1991;1097:128-32.
107. Leung PS, Watanabe Y, Munoz S, et al. Chromosome localization and RFLP analysis of PDC-E2: the major autoantigen of primary biliary cirrhosis. Autoimmunity 1993;14:335-40.
108. Scheuer PJ. Primary Biliary Cirrhosis. Proc R Soc Med 1967;60:1257-60.
109. Birkedal-Hansen H, Moore GWI, Bodden MK, et al. Matrix metalloproteinases: a critical review. Crit Rev Oral Biol Med 1993;4:197-250.
110. Cawston TE, Billington C. Editorial: metalloproteinases in the rheumatic diseases. J Pathol 1996;180:115-7.
111. Thomson MP, Arthur MJP. Mechanisms of liver damage and repair. Eur J Gastroenterol Hepatol 1999;11:949-55.
112. Benyon CR, Iredale JR, Goddard S, et al. Expression of tissue inhibitor of metalloproteinase 1 and 2 is increased in human fibrotic liver. Gastroenterology 1996;110:821-6.
113. Ye S, Eriksson P, Hamsten A, et al. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996;271:13055-60.
114. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995;73:209-15.
115. Satsangi J, Chapman RWG, Haldar N, et al. A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology 2001;121:124-30.
116. Quinoones S, Saus J, Otani Y, et al. Transcriptional regulation of human stromelysin. J Biol Chem 1989;264:8339-44.
117. Selmi C, Zuin M, Meda F, et al. Common variants of the matrix metalloproteinase-3 (stromelysin gene promoter in primary biliary cirrhosis. Gastroenterology 2002;122:247-8.
118. Donaldson PT, Clare MC, Craig W, et al. Transforming growth cell factor B-1 (TGFB1) gene polymorphisms in primary sclerosing cholangitis and primary biliary cirrhosis [abstract]. Hepatology 2000;32:174A.
119. Hugot J-P, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
120. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
121. Hampe J, Cuthbert A, Croucher PJP, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357:1925-8.
122. Huang QR, Morris D, Manolios N. Identification and characterisation of polymorphisms in the promoter region of human Apo-1/Fas (CD95) gene. Mol Immunol 1997;34:577-82.
123. Huang QR, Danis V, Lassere M, et al. Evaluation of a new apo-1/fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatol 1999;38:645-51.
124. Lenardo M, Chan FK-M, Hornung F, et al. Mature T lymphocyte apoptosis - immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 1999;17:221-53.
125. Pinkoski MJ, Brunner T, Green DR, et al. Fas and Fas ligand in the gut and liver. Am J Physiol 2000;278:354-66.
126. Siegel RM, Chan FK-M, Chun HJ, et al. The multifaceted role of Fas signalling in immune cell homeostasis and autoimmunity. Nat Immunol 2000;1:469-75.
127. Patel T, Steer CJ, Gores GJ. Apoptosis and the liver: a mechanism of disease, growth regulation, and carcinogenesis. Hepatology 1999;30:811-5.
128. Rust C, Gores GJ. Apoptosis and liver disease. Am J Med 2000;108:567-74.
129. Chervonsky AV. Apoptotic and effector pathways in autoimmunity. Curr Opin Immunol 1999;11:684-8.
130. Baragiotta A, Jones DEJ, Craggs A, et al. Investigation of CCR5D32 deletion and FAS/APO-1 (CD95) single nucleotide polymorphisms in primary biliary cirrhosis (PBC) [abstract]. Hepatology 2000;32:172A.
131. Perrow K, Taylor JJ, James OFW, et al. Caspase 8 gene polymorphism is associated with primary biliary cirrhosis [abstract]. Hepatology 2002;36:417A.
132. Vuoristo M, Farkkila M, Gylling H, et al. Expression and therapeutic response related to apolipoprotein E polymorphism in primary biliary cirrhosis. J Hepatol 2001;27:136-42.
133. Corpechot C, Benlian P, Barbu V, et al. Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis. J Hepatol 2001;35:324-8.
134. Springer JE, Cole DEC, Rubin LA, et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000;118:145-51.
135. Halmos B, Szalay F, Cserniczky T, et al. Association of primary biliary cirrhosis with vitamin D receptor BsmI genotype polymorphism in a Hungarian population. Dig Dis Sci 2000;45:1091-5.
136. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis. Hepatology 2002;35:126-31.
137. Pares A, Guanabens N, Alvarez L, et al. Collagen type Ialpha1 and vitamin D receptor gene polymorpisms and bone mass in primary biliary cirrhosis. Hepatology 2001;33:554-60.
138. Lakatos LP, Bajnok E, Hegedus D, et al. Vitamin D receptor, oestrogen receptor-alpha gene and interleukin-1 receptor antagonist gene polymorphisms in Hungarian patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2002;14:733-40.
139. Jones DEJ, James OFW, Bassendine MF. Primary biliary cirrhosis: Clinical and associated autoimmune features and natural history. Clin Liver Dis 1998;2:265-82.
140. Garrido MC, Hubscher SG. Accuracy of staging in primary biliary cirrhosis. J Clin Path 1996;49:556-9.